INZY News and Press, Inozyme Pharma Inc. From 12/03/20

The following slide deck was published by Inozyme Pharma, Inc. in conjunction with this event. For further details see: Inozyme Pharma (INZY) Investor Presentation - Slideshow

Inozyme Pharma (INZY): Q3 GAAP EPS of -$1.55 misses by $1.02.Cash, cash equivalents and investments of $171.7MPress Release For further details see: Inozyme Pharma EPS misses by $1.02

–  Submitted CTA for INZ-701 for the treatment of ENPP1 deficiency to United Kingdom regulatory agency – –  Received Rare Pediatric Disease and Fast Track Designations for INZ-701 for the treatment of ENPP1 deficiency – – ...

BOSTON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton, today announced the...

Gainers: Medigus (MDGS) +84%, Altimmune (ALT) +25%, Enlivex Therapeutics (ENLV) +16%, BiondVax Pharmaceuticals (BVXV) +16%, Aileron Therapeutics (ALRN) +15%.Losers: Gossamer Bio (GOSS) -34%, Avenue Therapeutics (ATXI) -17%, Emergent ...

– Dr. Sabbagh Brings More Than 20 Years of Experience in Rare Genetic Disorders and Mineral Metabolism Research Development Programs – – Company Announces Retirement of David Thompson , Ph.D. – – Company to ...

Inozyme Pharma (NASDAQ: INZY ) : Q2 GAAP EPS of -$7.57 misses by $6.03 . More news on: Inozyme Pharma, Inc., Earnings news and commentary, Read more ...

Upsized IPO in July 2020 raised $128.8 million in gross proceeds Submitted IND for INZ-701 for the treatment of ENPP1 deficiency; currently on FDA clinical hold pending completion of ongoing GLP toxicology studies Initiation of INZ-701 Phase 1/2 clinical trials anticipated in ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (“Inozyme”) (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization, today announced the closing of its initial public offerin...